Construction of a novel oncolytic adenoviral vector and its biological characteristics

Zhang,Mingzhi; Zhang,Xudong; Han,Zhiqiang; Chen,Xinfeng; Yang,Li; Sheng,Yuqiao; Wen,Jianguo

doi:10.3892/or.2012.2140

Construction of a novel oncolytic adenoviral vector and its biological characteristics

Authors:
- Mingzhi Zhang
- Xudong Zhang
- Zhiqiang Han
- Xinfeng Chen
- Li Yang
- Yuqiao Sheng
- Jianguo Wen
View Affiliations

Affiliations: Oncology Department of the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, P.R. China, Medical College of Zhengzhou University, Zhengzhou 450000, P.R. China, Institute of Clinical Medicine of the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, P.R. China
Published online on: November 15, 2012 https://doi.org/10.3892/or.2012.2140
Pages: 798-804

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In this study, we aimed to construct an effective and safe oncolytic adenoviral vector for cancer treatment with gene therapy. First, the promoter of the catalytic subunit of human telomerase (hTERTp), adenovirus early region 1a gene (E1A) and thymidine kinase gene of human herpes virus type 1 (HSV-1-TK) were amplified by using PCR from genomic DNA of 293A cells and wild-type HSV-1 (wHSV-1). These specially-prepared elements were inserted into an adenoviral shuttle vector in the opposite and the same directions of left inverted terminal repeat (L-ITR), respectively, to construct pENTR-E1A-IRES-TK-hTERTp (pEITH) and pENTR-hTERTp-E1A-IRES-TK (pHEIT). LR reaction between adenoviral shuttle vectors (pEITH and pHEIT) and the backbone vector DEST was carried out to establish adenoviral expression vectors pAd-E1A-IRES-TK-hTERTp (pAd-EITH) and pAd-hTERTp-E1A-IRES-TK (pAd-HEIT). Recombinant adenovirus Ad-EITH and Ad-HEIT were produced by transfecting 293A cells and purified for the subsequent studies of titer measurement, replication capability with and without acyclovir (ACV) and antitumor ability with and without ganciclovir (GCV) to evaluate the biological characteristics. Adenoviral shuttle vectors pEITH and pHEIT and expression vectors pAd-EITH and pAd-HEIT were successfully constructed, and recombinant adenoviruses Ad-EITH and Ad-HEIT with high titer were produced. The results of replication and cytotoxicity assays showed that Ad-EITH and Ad-HEIT replicated in the hTERTp (+) human nasopharyngeal carcinoma cell line CNE and expressed the TK gene effectively leading to the death of tumor cells. In addition, there were still some Ad-HEIT particles replicating in the hTERTp (-) human osteosarcoma U-2OS cells and human lung HFL-1 fibroblasts compared to Ad-EITH which was hardly able to replicate in U-2OS and HFL-1 cells. In addition, we also observed an interesting phenomenon, that the replication of Ad-EITH could be inhibited by antiviral drug ACV on account of the expression of HSV-1-TK gene making Ad-EITH sensitive to ACV. In conclusion, a novel oncolytic adenoviral vector Ad-EITH was produced which can be used for cancer-specific and efficient viral replication, and its safety is potentially improved as replication can be inhibited by ACV in vitro.

View Figures

View References

1	Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, Dolormente M, Dreiling L, El-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A, Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters KM, Putnam JB Jr, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL and Yin M: Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res. 9:93–101. 2003.PubMed/NCBI
2	Gabrilovich DI: INGN 201 (Advexin): adenoviral p53 gene therapy for cancer. Expert Opin Biol Ther. 6:823–832. 2006. View Article : Google Scholar : PubMed/NCBI
3	Liu XY: Targeting gene-virotherapy of cancer and its prosperity. Cell Res. 16:879–886. 2006. View Article : Google Scholar : PubMed/NCBI
4	Pin RH, Reinblatt M and Fong Y: Utilizing alpha-fetoprotein expression to enhance oncolytic viral therapy in hepatocellular carcinoma. Ann Surg. 240:659–666. 2004.PubMed/NCBI
5	Jakubczak JL, Ryan P, Gorziglia M, Clarke L, Hawkins LK, Hay C, Huang Y, Kaloss M, Marinov A, Phipps S, Pinkstaff A, Shirley P, Skripchenko Y, Stewart D, Forry-Schaudies S and Hallenbeck PL: An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res. 63:1490–1499. 2003.
6	Dilley J, Reddy S, Ko D, Nguyen N, Rojas G, Working P and Yu DC: Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. Cancer Gene Ther. 12:715–722. 2005. View Article : Google Scholar
7	Uchino J, Takayama K, Harada A, Kawakami Y, Inoue H, Curiel DT and Nakanishi Y: Infectivity enhanced, hTERT promoter-based conditionally replicative adenoviruses are useful for SCLC treatment. Cancer Gene Ther. 12:737–748. 2005. View Article : Google Scholar : PubMed/NCBI
8	Irving J, Wang Z, Powell S, O’Sullivan C, Mok M, Murphy B, Cardoza L, Lebkowski JS and Majumdar AS: Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther. 11:174–185. 2004. View Article : Google Scholar
9	Zou W, Luo C, Zhang Z, Liu J, Gu J, Pei Z, Qian C and Liu X: A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene. 23:457–464. 2004. View Article : Google Scholar : PubMed/NCBI
10	Tang XJ, Wang YP, Zhou QH, Che GW, Chen XH and Zhu DX: A study on selective killing effect of Hsv-tk/GCV driven by human telomerase catalytic subunit promoter on human lung cancer cell A549. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 24:148–152. 2007.(In Chinese).
11	Painter RG, Lanson NA Jr, Jin Z, Park F and Wang G: Conditional expression of a suicide gene by the telomere reverse transcriptase promoter for potential post-therapeutic deletion of tumorigenesis. Cancer Sci. 96:607–613. 2005. View Article : Google Scholar : PubMed/NCBI
12	Jiang YX, Lu Y, Liu TJ, Yang J, Chen Y and Fang YW: Using HSV-TK/GCV suicide gene therapy to inhibit lens epithelial cell proliferation for treatment of posterior capsular opacification. Mol Vis. 17:291–299. 2011.PubMed/NCBI
13	Zhang Y, Wang CW, Wang ZG, Ma DX, Pan S, Zhu SG, Li F and Wang B: Construction of double suicide genes system controlled by MDR1 promoter with targeted expression in drug-resistant glioma cells. J Neurooncol. 86:3–11. 2008. View Article : Google Scholar : PubMed/NCBI
14	Huagn Y, Xu YM, Zhang JW, Ren XH and Suo AQ: Effects of estrogen on P-Tau, ChAT and nerve growth factor protein expressions in the brain tissue of rats with Alzheimer’s disease. Nan Fang Yi Ke Da Xue Xue Bao. 30:2408–2410. 2010.(In Chinese).
15	Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Lecluse Y, van Beusechem VW, Gerritsen WR, Kirn DH and Vassal G: Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts. Br J Cancer. 89:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
16	Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, Randlev B, Gillenwater AM, Bruso P, Kaye SB, Hong WK and Kirn DH: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 6:879–885. 2000. View Article : Google Scholar : PubMed/NCBI
17	Xing L and Tikoo SK: E1A promoter of bovine adenovirus type 3. J Gen Virol. 87:3539–3544. 2006. View Article : Google Scholar : PubMed/NCBI
18	Yamamoto M, Davydova J, Takayama K, Alemany R and Curiel DT: Transcription initiation activity of adenovirus left-end sequence in adenovirus vectors with e1 deleted. J Virol. 77:1633–1637. 2003. View Article : Google Scholar : PubMed/NCBI
19	Li C, Hirsch M, Carter P, Asokan A, Zhou X, Wu Z and Samulski RJ: A small regulatory element from chromosome 19 enhances liver-specific gene expression. Gene Ther. 16:43–51. 2009. View Article : Google Scholar : PubMed/NCBI
20	Reed LJ and Muench H: A simple method of estimating fifty percent endpoints. Am J Hygiene. 27:493–497. 1938.
21	Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A and McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 274:373–376. 1996. View Article : Google Scholar : PubMed/NCBI
22	Niculescu-Duvaz I and Springer CJ: Introduction to the background, principles, and state of the art in suicide gene therapy. Mol Biotechnol. 30:71–88. 2005. View Article : Google Scholar : PubMed/NCBI
23	Zhang X, Zhao L, Hang Z, Guo H and Zhang M: Evaluation of HSV-1 and adenovirus vector-mediated infection, replication and cytotoxicity in lymphoma cell lines. Oncol Rep. 26:637–644. 2011.PubMed/NCBI